NASDAQ$PAYS

Paysign Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported solid fourth quarter and full-year 2023 financial results, meeting or exceeding revenue and adjusted EBITDA guidance.

Paysign reported a strong year with a 24% increase in revenue and a 21% increase in adjusted EBITDA. The patient affordability business experienced significant growth, and the company anticipates continued upward trajectory across all business units in the coming year.

  • Revenue increased by 24% year-over-year.
  • Adjusted EBITDA increased by 21% year-over-year.
  • Plasma revenue grew by 21%.
  • Patient affordability business experienced 172% revenue growth.

Headline financials

Total Revenue

$13.7M

Previous: $10.6M+28.9%
EPS (adj)

$0.10

Previous: $0.01+900.0%
Avg. Revenue/Plasma Ctr

$8.3K

No prior period
Capital Expenditures

$44.4K

Previous: $29.5K+50.5%
Net Income

$5.62M

Previous: $713K+688.5%
Operating Income

$632K

Previous: $315K+101.0%
Gross Profit

$5.96M

Previous: $5.51M+8.2%
Stock-Based Comp

$695K

Previous: $654K+6.3%

Revenue & EPS history

Paysign · Revenue · Quarterly

$13.7M

Q4 2023+28.9%vs Q4 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

Paysign expects continued growth in 2024, with revenue projected to be between $54.5 million and $56.7 million. Pharma revenue is expected to grow significantly, and the company anticipates continued investments in people and technology.

Tailwinds

  • Total revenues are expected to be in the range of $54.5 million to $56.7 million, reflecting year-over-year growth of 15% to 20%.
  • Pharma revenue is expected to grow at least 100% year-over-year.
  • Gross profit margins are expected to be between 52.0% to 54.0%.
  • The company expects to generate interest income of $2.6 million to $2.9 million.
  • Net income is expected to be in the range of $2.0 million to $3.0 million, or $0.04 to $0.06 per diluted share, and adjusted EBITDA to be in the range of $8.0 million to $9.0 million, or $0.15 to $0.17 per diluted share.

Headwinds

  • Revenue for the first quarter of 2024 is expected to reflect the seasonal impact of tax refunds on the plasma business.
  • Operating expenses are expected to be between $29.0 and $31.0 million as we continue to make investments in people and technology.
  • Operating expenses for Q1 2024 are expected to be between $7.0 million to $7.5 million.
  • Depreciation and amortization are expected to be between $6.0 million and $6.5 million.
  • Stock-based compensation is expected to be between $2.7 million and $3.0 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro